Trial Profile
COAST -1: Clinical Knee Osteoarthritis Symptom Treatment 1 Study. A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects With Knee Osteoarthritis Associated With Bone Marrow Lesions.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Acronyms COAST-1
- Sponsors Axsome Therapeutics
- 08 Jan 2019 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2020.
- 08 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2018 According to an Axsome Therapeutics media release, screening in the trial was paused pending the results of the interim analysis and is anticipated to resume after the final readout from the STRIDE-1 trial